SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     



J Nucl Med. 2008; 49 (Supplement 1):348P
This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Frenkel, A.
Right arrow Articles by Dimitrakopoulou-Strauss, A.
PubMed
Right arrow Articles by Frenkel, A.
Right arrow Articles by Dimitrakopoulou-Strauss, A.

Oncology-Clinical Diagnosis: Solid Tumors

Clinical Diagnosis-Solid Tumors Posters

Dynamic FDG-PET/CT as an indicator of tumor aggressiveness and patient outcome in pancreatic cancer

Alex Frenkel1, Ora Israel1, Riad Haddad2, Ron Epelbaum1, Rachel Bar Shalom1, Ludwig Strauss3 and Antonia Dimitrakopoulou-Strauss3

1 Rambam HealthCare Campus, Haifa, Israel; 2 Carmel Medical Center, Haifa, Israel; 3 German Cancer Research Center, Heidelberg, Germany

1470

Objectives: Present study evaluates a kinetic FDG-PET model as an indicator for defining tumor aggressiveness and prognosis in patients (pts) with pancreatic cancer.

Methods: Fifty pts with known or suspected cancer of the pancreas were referred for FDG-PET/CT. A dynamic single field of view PET acquisition over the region of the pancreas was initiated with the administration of 15 mCi FDG and sequential data were sampled for 60 minutes. Tracer kinetics were measured. Fractional blood volume associated with vessel density (VB), kinetic parameters (K1, K2, K3, K4) and global FDG influx were calculated using a two-compartmental model and the fractal dimension (FD) using a non-compartmental model. Whole body PET/CT was performed at 2 hours post-injection. Statistical significance was assessed using Cox proportional-hazards for overall survival analysis and logistic multivariate analysis to compare kinetic tracer behavior in FDG-avid pancreatic cancer in pts with localized vs. metastatic disease.

Results: No increased FDG uptake was found in 22 pts and 28 pancreatic lesions were FDG-avid. Pancreatic cancer was diagnosed in 24 pts including 12 with localized and 12 with metastatic lesions. 11 pts died during a follow up period of 12 months. K1 was the single statistically significant variable predicting overall survival (P<0.01). There was no significant difference in kinetic parameters in the primary tumor between pts with localized and metastatic disease.

Conclusions: Present results suggest that K1 may represent the prognostic kinetic variable predicting outcome in patients with newly diagnosed cancer of the pancreas.





This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Frenkel, A.
Right arrow Articles by Dimitrakopoulou-Strauss, A.
PubMed
Right arrow Articles by Frenkel, A.
Right arrow Articles by Dimitrakopoulou-Strauss, A.